Japan's pharmaceutical company compliance has changed! New revised Code of Conduct to be implemented from October

Medicines Network September 24th, from October 1st, Japan's domestic pharmaceutical companies to implement a new code of conduct! The following big rice simple sharing, for concerned pharmaceutical companies to promote regulations and compliance requirements of the global dynamics of small partners to understandremember before the big mite shared to everyone, on April 1 this year, Japan's Ministry of Health, Labour and Welfare officially began to implement the "prescription drug sales information guidance", which is the Ministry of Health and Welfare in order to regulate the sales information activities of pharmaceutical companies, unreasonable use or misuse of the behavior to correct a major / regulation, Japanese associations and pharmaceutical companies have given great attentionsince then, the Japan Pharmaceutical Association first from a non-sales perspective of the pharmaceutical companies in recent years, the establishment of MSL, MA positions to develop behavior guidelines, regulate their interaction with external experts, on April 2 issued the MA Act Consensus Statement and MSL Behavior Consensus Statementthe subsequent revision of the Code of Conduct for pharmaceutical companies and a consultation with member companies in July, and the latest news from Japan, as of October 1, the Japan Pharmaceutical Association will fully implement the revised Code of Conductthe revision was implemented after japan's Ministry of Health, Labour and Welfare implemented the Guidelines for the Provision of Prescription Drug Sales Information, which has positioned the pharmaceutical industry to a higher ethical standard, which has positioned it as one of the regulations that pharmaceutical companies in Japan must comply with, and which is in line with Japan'sPharmaceuticalandMedical DevicesAct and the PharmaceuticalEthics Program, the Prescription Drug and Sales Industry Fair Competition Agreement, and the Pharmaceutical Compliance
Guidedrug company employees to violate the law, blame the executive!the Code of Conduct of the Japan Pharmaceutical Association is based on the Code of Conduct of the International Federation of Pharmaceutical Associations (IFPMA), the first edition was published in January 2013 and revised in May 2017 and November 2018the new revision did not make major changes to the main content, no new prohibitions, etc, the changes mainly focused on two points, one is that the pharmaceutical manufacturing and distributors of the management team should be responsible for all employees of the company's sales information activities related to business conduct (note that all employees), which is based on the Ministry of Health, Labour and Welfare of Japan, "prescription drug sales information provision guide" requirementsthe Ministry of Health, Labour and Welfare has previously mentioned that Japan's Ministry of Health, Labour and Welfare has developed the "Prescription Drug Sales Information Provides Guide" to ensure that pharmaceutical companies can provide doctors with appropriate information about prescription drugs, because in sales information provision activities, sometimes vague exaggeration or false information, but because of oral communication, difficult to verify, these actions affect the correct use of prescription drugsanother point is that in recent years, in order to promote advances in medical science and health care, pharmaceutical companies have used new technologies to interact with medicine and science through new responsibilities, such as the establishment of medical liaison officers (MSL) positions, which, although not specifically required, provide for the provision of corporate sales information activities In fact, the constraints are large, in order to avoid conflict with the Ministry of Health and Health's Guide, previously the Pharmaceutical Association and pharmaceutical on behalf of different duties of MSL, also issued a "consensus", requiring that independent of business activities MSL, MA, should also be in compliance with the Prescription Drug Sales Information Provide Sini as a prerequisite for activities to avoid unclear boundaries of interaction and misleading medical personnel and the public Another change revision is that the Guidelines require pharmaceutical companies to establish a Code of Conduct and Compliance Promotion Committee since then, after the Full Implementation of the Code, the Pharmaceutical Association has conducted an investigation into member companies and established a reasonable mechanism to manage the compliance status of member companies and compare them prior to implementation, in the hope that the new Guidelines will require a positive corporate culture that takes root in the industry